BioSpace News Archive

Abcam plc announces that, following release on 20 March 2023 of its final results for the year ended 31 December 2022 on Form 20-F with the Securities and Exchange Commission, the Abcam plc Annual Report and Accounts 2022 have been published and are available on the Abcam plc website

Neogen Corporation (NASDAQ: NEOG) announced today the results of the third quarter ended February 28, 2023.

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced the appointment of Neil Gallagher, M.D., Ph.D., to the role of President, Head of Research and Development (R&D), effective April 10, 2023.

ThirtyFiveBio Limited emerged from stealth and announced that it will present the first data from its GPR35 antagonist program at the upcoming American Association for Cancer Research Annual Meeting 2023.

Takeda (TSE:4502/NYSE:TAK) today confirmed that the New England Journal of Medicine (NEJM) has published positive data from the Phase 4 EARNEST study of vedolizumab for the treatment of chronic pouchitis.

Avidity Biosciences, Inc. (Nasdaq: RNA) today provided an update on the Phase 1/2 MARINA™ trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1), an underrecognized, progressive and often fatal neuromuscular disease with no approved treatment options.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced financial results for the year ended December 31, 2022.

Zevra Therapeutics announced that it has appointed Wendy L. Dixon, Ph.D., to the Company’s Board of Directors, effective immediately following the conclusion of the 2023 Annual Meeting of Stockholders, to fill the vacancy resulting from Dr. Travis Mickle’s resignation from the Board effective as of the day of the 2023 Annual Meeting to be held on April 25, 2023.

CorMedix Inc. announced financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent business developments.

IMUNON, Inc. announced financial results for the year ended December 31, 2022, and provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer.